NEW YORK(GenomeWeb) – Nuclea Biotechnologies this month will launch a set of mass spectrometry assays covering roughly 55 protein biomarkers as part of its recent move into mass spec-based proteomics.

The company plans to follow that launch with the release toward the end of the year of a multiplex mass spec assay for insulin, proinsulin, and c-peptide, which it will offer as a clinical test out of the new CLIA facility it is building in Cambridge, Massachusetts.